4,5-Dimethoxy-1-Cyanobenzocyclobutane CAS 35202-54-1 Purity >99.0% (HPLC) Ivabradine Hydrochloride Intermediate Factory

Short Description:

Name: 4,5-Dimethoxy-1-Cyanobenzocyclobutane 

CAS: 35202-54-1

Purity: >99.0% (HPLC)  

Appearance: Off-White to Light Brown Powder

Intermediate of Ivabradine Hydrochloride

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 4,5-Dimethoxy-1-Cyanobenzocyclobutane
Synonyms 4,5-Dimethoxy-1-Benzocyclobutenecarbonitrile; 1-Cyano-4,5-Dimethoxybenzocyclobutene; 3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-Carbonitrile; Ivabradine Hydrochloride Intermediate
CAS Number 35202-54-1
CAT Number RF-PI1809
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C11H11NO2
Molecular Weight 189.21
Melting Point  83.0~84.0℃
Density  1.18
Solubility (Soluble in) Methanol
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Off-White to Light Brown Powder
Identification HPLC/UV Complies
Purity / Analysis Method >99.0% (HPLC)  
Loss on Drying <0.50% (Dry it at 40℃ till constant weight )
Residue on Ignition <0.10%
Related Substances
Individual Impurity <0.50%
Total Impurities <1.00%
Heavy Metals <10ppm
Test Standard Enterprise Standard
Usage Intermediate of Ivabradine Hydrochloride (CAS: 148849-67-6)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

4,5-Dimethoxy-1-Cyanobenzocyclobutane (CAS: 35202-54-1) is an intermediate of Ivabradine Hydrochloride (CAS: 148849-67-6). Ivabradine Hydrochloride has evolved as a specific inhibitor of If current through its contact with f-channels on the intracellular side of the plasma membrane. As a consequence, Ivabradine reduces the speed of diastolic depolarization and decreases heart rate. It has been approved for the treatment of chronic stable angina and provides a viable alternative to patients with a contraindication or intolerance of b-blockers. Evaluation is also underway for the potential treatment of ischemic heart disease.

  • Write your message here and send it to us